
Spero Therapeutics, Inc.: shareholders and insiders
Price
$0.90
November 17, 2026Market cap $52M
What Ploutos Investor adds for Spero Therapeutics
Part of Ploutos Investor, €9.99 a month
- The full history: 10 fiscal years, from 2016
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Insiders and their shares
Purchases and sales by officers and directors from Nov 18, 2025 to Nov 10, 2026, from their own Form 4 filings.
Bought on the market
–
nobody
Sold on the market
$499.1K
2 people
From Nov 18, 2025 to Nov 18, 2026, the days the chart shows. Change its range and the figures follow.
How the sales were made, as a share of their value
- Under a set plan0%
- The rest100%
By year
Insiders' open-market purchases (up) and sales (down), by value, since Nov 18, 2025, on a log scale: each gridline is ten times the last. From the SEC's quarterly data sets of Form 4 filings.
2026·no buys·sold $499.1K by 2 people
- 2025: no buys, no sales
- 2026: no buys, sold $499.1K by 2 people
- Nov 9, 2026Esther RajaveluChief Executive Officer and Chief Financial OfficerKind
- Aug 3, 2026Debra ZackChief Medical OfficerKind10b5-1
- Jun 23, 2026Milind DeshpandeDirectorKind
- Jun 23, 2026Kathleen TregoningDirectorKind
- Jun 23, 2026Cynthia SmithDirectorKind
- Jun 23, 2026Patrick V.j.j. VinkDirectorKind
- Jun 23, 2026Frank E ThomasDirectorKind
- Jun 23, 2026Scott Thomas JacksonDirectorKind
- Jun 23, 2026John C Pottage JrDirectorKind
- May 4, 2026Esther RajaveluKind
- Feb 6, 2026Timothy KeutzerChief Operating OfficerKind
- Feb 6, 2026Esther RajaveluKind
- Feb 6, 2026Esther RajaveluKind
- Feb 4, 2026Timothy KeutzerChief Operating OfficerKind
- Feb 3, 2026Timothy KeutzerChief Operating OfficerKind
- Feb 2, 2026Timothy KeutzerChief Operating OfficerKind
- Feb 2, 2026Esther RajaveluKind
| Date | Person | Kind | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Nov 9, 2026 | Esther RajaveluChief Executive Officer and Chief Financial Officer | 40.9K | $1.04 | $42.5K | Form 4 | |
| Aug 3, 2026 | Debra ZackChief Medical Officer | 10b5-1 | 162.3K | – | – | Form 4 |
| Jun 23, 2026 | Milind DeshpandeDirector | 10.0K | – | – | Form 4 | |
| Jun 23, 2026 | Kathleen TregoningDirector | 10.0K | – | – | Form 4 | |
| Jun 23, 2026 | Cynthia SmithDirector | 10.0K | – | – | Form 4 | |
| Jun 23, 2026 | Patrick V.j.j. VinkDirector | 10.0K | – | – | Form 4 | |
| Jun 23, 2026 | Frank E ThomasDirector | 10.0K | – | – | Form 4 | |
| Jun 23, 2026 | Scott Thomas JacksonDirector | 10.0K | – | – | Form 4 | |
| Jun 23, 2026 | John C Pottage JrDirector | 10.0K | – | – | Form 4 | |
| May 4, 2026 | Esther Rajavelu | 25.2K | $2.51 | $63.4K | Form 4 | |
| Feb 6, 2026 | Timothy KeutzerChief Operating Officer | 18.7K | $2.36 | $44.0K | Form 4 | |
| Feb 6, 2026 | Esther Rajavelu | 50.8K | $2.36 | $119.9K | Form 4 | |
| Feb 6, 2026 | Esther Rajavelu | 37.1K | $2.36 | $87.6K | Form 4 | |
| Feb 4, 2026 | Timothy KeutzerChief Operating Officer | 3,471 | $2.24 | $7.8K | Form 4 | |
| Feb 3, 2026 | Timothy KeutzerChief Operating Officer | 24.2K | $2.14 | $51.8K | Form 4 | |
| Feb 2, 2026 | Timothy KeutzerChief Operating Officer | 18.9K | $2.20 | $41.6K | Form 4 | |
| Feb 2, 2026 | Esther Rajavelu | 18.4K | $2.20 | $40.6K | Form 4 |
From the Form 4s insiders file with the SEC within two business days of each trade. Before Jun 25, 2026 the table lists open-market purchases and sales only (no grants, option exercises or tax withholding), from the SEC's quarterly data sets. The 10b5-1 mark comes from the form's own box (since April 2023) or from a footnote of the filing that names the plan, where there is one.
Insiders and their shares
Every buy and sale by SPRO's officers and directors from 2017 up to November 17, 2025, 9 more calendar years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 3 years.
and 4 more, back to 2017
Major holders (over 5%)
Whoever comes to own more than 5% of a class of shares reports it to the SEC on Schedule 13D or 13G. Here is each holder's latest filing.
- GskShare of class16.4%
| Holder | Kind of stake | Share of class | Shares | Filed | Filing |
|---|---|---|---|---|---|
| Gsk | 16.4% | 9.19M | Mar 28, 2025 | 13D/A |
Fell to 5% or less (1)
Holders whose latest filing says they hold 5% or less. After it they need not file again, so what they hold today is not known.
- Anson Funds Management LP2.90%Aug 14, 202513G/A
From the Schedule 13D and 13G filed with the SEC since Dec 18, 2024, when they became structured data. A holder who has filed nothing since then is not shown here. A 13D is updated within two business days of any material change, a 13G up to 45 days after the quarter of the change, so the shares are those of the filing. The large managers also appear in the 13Fs.
Well-known managers
Which of the about 30 investment managers we track held the shares at the quarter end, and what they changed from the quarter before.
- Point72 (Cohen)In the quarter+75%
- Citadel Advisors (Griffin)In the quarter
- Millennium Mgmt (Englander)In the quarter
- Renaissance TechnologiesIn the quarter+49%
| Manager | Shares | In the quarter | Value | % of their portfolio |
|---|---|---|---|---|
| Point72 (Cohen) | 104.4K | +75% | $200.0K | 0.00% |
| Citadel Advisors (Griffin) | – | – | 0.00% | |
| Millennium Mgmt (Englander) | 19.3K | $0 | 0.00% | |
| Renaissance Technologies | 1.41M | +49% | $1.7M | 0.00% |
From the 13Fs managers file with the SEC up to 45 days after each quarter end. They show only long positions on that day, not short sales or what has changed since. No recent 13F: Pershing Square (Ackman), Scion (Burry).
Short interest
How many of the company's shares have been sold borrowed and not yet bought back, twice a month.
On Oct 15, 2026, 1.45% of its shares outstanding were held short, +5.8% since the report before.
- Shares held short
- 840.5K
- 1.45%
- Since the report before794.5K on Sep 30, 2026
- +5.8%
- 1.5
- 558.5K
- More days to cover thanof 4,578 US-listed companies with enough volume
- 20%
- Report date
- Oct 15, 2026
- Shares held short
- Oct 31, 2023: Shares held short 1.26M
- Nov 15, 2023: Shares held short 1.13M
- Nov 30, 2023: Shares held short 1.08M
- Dec 15, 2023: Shares held short 976.5K
- Dec 29, 2023: Shares held short 789.0K
- Jan 12, 2024: Shares held short 680.2K
- Jan 31, 2024: Shares held short 707.1K
- Feb 15, 2024: Shares held short 619.0K
- Feb 29, 2024: Shares held short 564.0K
- Mar 15, 2024: Shares held short 613.9K
- Mar 28, 2024: Shares held short 653.8K
- Apr 15, 2024: Shares held short 513.2K
- Apr 30, 2024: Shares held short 468.0K
- May 15, 2024: Shares held short 494.2K
- May 31, 2024: Shares held short 483.9K
- Jun 14, 2024: Shares held short 434.1K
- Jun 28, 2024: Shares held short 420.0K
- Jul 15, 2024: Shares held short 390.3K
- Jul 31, 2024: Shares held short 355.9K
- Aug 15, 2024: Shares held short 376.7K
- Aug 30, 2024: Shares held short 409.1K
- Sep 13, 2024: Shares held short 385.1K
- Sep 30, 2024: Shares held short 384.3K
- Oct 15, 2024: Shares held short 387.1K
- Oct 31, 2024: Shares held short 625.2K
- Nov 15, 2024: Shares held short 546.8K
- Nov 29, 2024: Shares held short 493.8K
- Dec 13, 2024: Shares held short 451.2K
- Dec 31, 2024: Shares held short 412.6K
- Jan 15, 2025: Shares held short 354.1K
- Jan 31, 2025: Shares held short 376.8K
- Feb 14, 2025: Shares held short 429.6K
- Feb 28, 2025: Shares held short 424.7K
- Mar 14, 2025: Shares held short 437.2K
- Mar 31, 2025: Shares held short 498.1K
- Apr 15, 2025: Shares held short 801.3K
- Apr 30, 2025: Shares held short 645.2K
- May 15, 2025: Shares held short 636.7K
- May 30, 2025: Shares held short 3.48M
- Jun 13, 2025: Shares held short 1.61M
- Jun 30, 2025: Shares held short 1.70M
- Jul 15, 2025: Shares held short 1.22M
- Jul 31, 2025: Shares held short 1.38M
- Aug 15, 2025: Shares held short 927.2K
- Aug 29, 2025: Shares held short 504.0K
- Sep 15, 2025: Shares held short 458.6K
- Sep 30, 2025: Shares held short 549.5K
- Oct 15, 2025: Shares held short 315.7K
- Oct 31, 2025: Shares held short 476.1K
- Nov 14, 2025: Shares held short 615.7K
- Nov 28, 2025: Shares held short 825.7K
- Dec 15, 2025: Shares held short 1.06M
- Dec 31, 2025: Shares held short 946.8K
- Jan 15, 2026: Shares held short 1.04M
- Jan 30, 2026: Shares held short 941.7K
- Feb 13, 2026: Shares held short 715.7K
- Feb 27, 2026: Shares held short 574.0K
- Mar 13, 2026: Shares held short 537.4K
- Mar 31, 2026: Shares held short 605.3K
- Apr 15, 2026: Shares held short 737.7K
- Apr 30, 2026: Shares held short 1.18M
- May 15, 2026: Shares held short 1.65M
- May 29, 2026: Shares held short 1.71M
- Jun 15, 2026: Shares held short 1.83M
- Jun 30, 2026: Shares held short 2.86M
- Jul 15, 2026: Shares held short 2.11M
- Jul 31, 2026: Shares held short 1.51M
- Aug 14, 2026: Shares held short 1.45M
- Aug 31, 2026: Shares held short 1.21M
- Sep 15, 2026: Shares held short 976.5K
- Sep 30, 2026: Shares held short 794.5K
- Oct 15, 2026: Shares held short 840.5K
As brokers report them to the regulator twice a month, mid-month and at month end, published about eight business days later. A short position is shares sold borrowed and not yet bought back. The share count is the one the company's market value is figured on, from its filings. Days to cover is the shares held short over the average daily volume of the weeks between two reports.
Short sales in daily trading47.2% of the shares in the last 14 sessions' reported trades were short sales.
In the last 14 sessions, 47.2% of the shares in the reported trades were short sales, against 33.1% in the 14 before.
- Last 14 sessionsOct 29, 2026 – Nov 17, 2026
- 47.2%
- The 14 beforeOct 9, 2026 – Oct 28, 2026
- 33.1%
- Change
- +14.1 pts
- Short sales a dayon average, of 172.6K shares
- 81.5K
- More than atof 3,666 US-listed companies, same days
- 39%
- Median of alleight in ten from 34.6% to 63.7%
- 50.3%
- Short sales
- Oct 9, 2026: Short sales 29.5%
- Oct 12, 2026: Short sales 28.6%
- Oct 13, 2026: Short sales 34.4%
- Oct 14, 2026: Short sales 36.3%
- Oct 15, 2026: Short sales 37.6%
- Oct 16, 2026: Short sales 20.6%
- Oct 19, 2026: Short sales 44.9%
- Oct 20, 2026: Short sales 24.9%
- Oct 21, 2026: Short sales 14.2%
- Oct 22, 2026: Short sales 33%
- Oct 23, 2026: Short sales 50%
- Oct 26, 2026: Short sales 44.2%
- Oct 27, 2026: Short sales 35.9%
- Oct 28, 2026: Short sales 23.6%
- Oct 29, 2026: Short sales 40.7%
- Oct 30, 2026: Short sales 50.5%
- Nov 2, 2026: Short sales 30.6%
- Nov 3, 2026: Short sales 42.2%
- Nov 4, 2026: Short sales 42.7%
- Nov 5, 2026: Short sales 50.4%
- Nov 6, 2026: Short sales 40.6%
- Nov 9, 2026: Short sales 43.3%
- Nov 10, 2026: Short sales 41.6%
- Nov 11, 2026: Short sales 53.4%
- Nov 12, 2026: Short sales 64.7%
- Nov 13, 2026: Short sales 54.8%
- Nov 16, 2026: Short sales 52.2%
- Nov 17, 2026: Short sales 54.2%
This is not the number of shares sold short today: it measures short sales within each day's trading, and only trades made off the exchanges. Much of it is market makers, who sell shares they do not have to fill buyers' orders and cover soon after, so for a heavily traded stock the share is often around half.
What the insiders hold
The shares each insider reports holding after their latest trade (Form 4), for those who traded on the market in the last three years.
- Sath ShuklaCEO & PresidentDirectly1.89M
- Esther RajaveluSee RemarksDirectly946.0K
- Kamal HamedChief Medical OfficerDirectly788.1K
- Timothy KeutzerChief Operating OfficerDirectly742.5K
- Ankit MahadeviaDirectorDirectly703.3K
- Tamara L JosephChief Legal OfficerDirectly531.6K
- Debra ZackChief Medical OfficerDirectly162.3K
- Milind DeshpandeDirectorDirectly101.5K
- Kathleen TregoningDirectorDirectly85.0K
- Cynthia SmithDirectorDirectly85.0K
- Patrick V.j.j. VinkDirectorDirectly85.0K
- Frank E ThomasDirectorDirectly85.0K
- Scott Thomas JacksonDirectorDirectly85.0K
- John C Pottage JrDirectorDirectly85.0K
| Person | Directly | Indirectly | After the trade of | Filing |
|---|---|---|---|---|
| Sath ShuklaCEO & President | 1.89M | – | Feb 5, 2025 | Form 4 |
| Esther RajaveluSee Remarks | 946.0K | – | Nov 9, 2026 | Form 4 |
| Kamal HamedChief Medical Officer | 788.1K | – | Feb 2, 2024 | Form 4 |
| Timothy KeutzerChief Operating Officer | 742.5K | – | Feb 6, 2026 | Form 4 |
| Ankit MahadeviaDirector | 703.3K | – | Aug 28, 2025 | Form 4 |
| Tamara L JosephChief Legal Officer | 531.6K | – | Feb 2, 2024 | Form 4 |
| Debra ZackChief Medical Officer | 162.3K | – | Aug 3, 2026 | Form 4 |
| Milind DeshpandeDirector | 101.5K | – | Jun 23, 2026 | Form 4 |
| Kathleen TregoningDirector | 85.0K | – | Jun 23, 2026 | Form 4 |
| Cynthia SmithDirector | 85.0K | – | Jun 23, 2026 | Form 4 |
| Patrick V.j.j. VinkDirector | 85.0K | – | Jun 23, 2026 | Form 4 |
| Frank E ThomasDirector | 85.0K | – | Jun 23, 2026 | Form 4 |
| Scott Thomas JacksonDirector | 85.0K | – | Jun 23, 2026 | Form 4 |
| John C Pottage JrDirector | 85.0K | – | Jun 23, 2026 | Form 4 |
A lower bound: it counts only the 14 officers and directors with a market trade since Nov 19, 2023. Anyone who neither bought nor sold since is not here, whatever they hold. The share is against the share count on the latest 10-K's cover.
The ETFs that hold it
Which of the 345 US equity ETFs we track hold the stock, and at what weight, from the funds' N-PORT filings.
- IWCiShares Micro-Cap ETFWeight in the fund0.02%
- VXFVanguard Extended Market Index FundWeight in the fund0.00%
- DFASDimensional U.S. Small Cap ETFWeight in the fund0.00%
- VTIVanguard Total Stock Market Index FundWeight in the fund0.00%
4 of the 345 ETFs we track, not of every ETF on the market. The ten largest weights. Positions as each fund filed them in its latest N-PORT.
Institutional investors by quarter
Every manager that reports positions to the SEC (Form 13F), quarter by quarter: how many hold the stock, how many shares and dollars between them, and who entered, left, added or trimmed during the quarter.
- Managers
- Q3 2025: Managers 47
- Q4 2025: Managers 56
- Q1 2026: Managers 51
- Q2 2026: Managers 60
Institutional investors by quarter
The fund managers holding SPRO, quarter by quarter, from Q2 2013 to Q2 2025, 41 more quarters
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 12 quarters.
Q2 2026: 60 managers held 21.47M shares, worth $48M. During the quarter 22 opened a position, 13 closed one, 16 added and 6 trimmed.
The largest holders, Q2 2026
- GskIn the quarter
- PfizerIn the quarter
- Vanguard Capital ManagementIn the quarter+13%
- Renaissance TechnologiesIn the quarter-20%
- AlphabetIn the quarter
- Susquehanna International GroupIn the quarter+128%
- BlackRockIn the quarter+37%
- Geode Capital ManagementIn the quarter+8.9%
- Raymond James FinancialIn the quarter
- Two Sigma InvestmentsIn the quarter-57%
| Manager | Shares | In the quarter | Value |
|---|---|---|---|
| Gsk | 9.19M | $20M | |
| Pfizer | 2.36M | $5.3M | |
| Vanguard Capital Management | 2.04M | +13% | $4.5M |
| Renaissance Technologies | 947.9K | -20% | $2.1M |
| Alphabet | 890.0K | $2.0M | |
| Susquehanna International Group | 759.3K | +128% | $1.7M |
| BlackRock | 594.4K | +37% | $1.3M |
| Geode Capital Management | 566.3K | +8.9% | $1.3M |
| Raymond James Financial | 521.7K | $1.2M | |
| Two Sigma Investments | 382.8K | -57% | $846.0K |
From the SEC's Form 13F data sets, Q3 2025 to Q2 2026: the long positions of every manager with more than $100 million under management, as filed up to 45 days after each quarter end. Short positions and options are not in them. Shares as reported each quarter, not adjusted for splits. The stock is matched by its CUSIP, through the SEC's fails-to-deliver files.
Pay against performance, the say-on-pay vote, buybacks by quarter and trading plans are read for S&P 500 companies only.
The full analysis
What do Spero Therapeutics's filings show?
Who buys and sells is one part of Spero Therapeutics's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Have SPRO's insiders bought or sold?
From Jun 25, 2026 to Nov 10, 2026 Spero Therapeutics's insiders bought 0 and sold $42.5K of shares on the market. 0% of the sales were under set 10b5-1 plans.
Which well-known managers hold SPRO?
4 of the managers we track held the shares on Sep 30, 2026. The largest position was Renaissance Technologies's, worth $1.7M.
Is every insider transaction a purchase or a sale?
No. Many are part of their pay: share awards, option exercises and shares the company keeps for the tax. Only code P is a purchase with their own money, and code S a sale on the market.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.